The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
Yao YaoXiaoye LiZi WangShikun XuQianzhou LvPublished in: International journal of clinical pharmacy (2023)
A combination of high fibrinogen and HRPR may identify recurrent adverse ischemic events over 12 months. Ticagrelor exhibited more potent platelet inhibition and a better prognosis than clopidogrel.
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- antiplatelet therapy
- coronary artery disease
- ischemia reperfusion injury
- cerebral ischemia
- emergency department
- atrial fibrillation
- subarachnoid hemorrhage
- electronic health record